Biomarkers & Companion Diagnostics

8:30

Precision Medicine Challenges across Start-up to Pharma

Julie Engel

Sr. Director, Molecular Diagnostics

Cyteir Therapeutics

9:15

Jounce: a Translational Approach to Identify Optimal Patient Selection to Maximize Clinical Outcomes

Johan Baeck

VP, Clinical Development and Medical Affairs

Jounce Therapeutics

10:30

Biomarker/ CDx Panel Discussion

Moderator: Theresa Zhang

VP, Translational Science

Repare Therapeutics

11:15

ctDNA dynamics in EGFR mutant Lung Cancer

Juliann Chmielecki

Associate Director, Translational Science

AstraZeneca

11:45

Novel Approaches

2:00

Assessment of PARP inhibitor activity in lung cancer tumor models

Kevin Coleman

Executive Director Translational Research & Development Experimental Biology

TESARO, Inc. / GSK

2:30

The discovery and clinical development of pralsetinib, a precision therapy for RET-altered cancers

Stephen Miller

Vice President, Translational Medicine

Blueprint Medicines

3:00

Targeting extrachromosomal DNA (ecDNA), a new approach to treating cancers with high copy number gene amplification

Jason Christiansen

Chief Technology Officer

Boundless Bio

3:30

XMT-1536: A NaPi2b-Targeted Antibody-Drug Conjugate for Ovarian Cancer and NSCLC Adenocarcinoma.

Joshua Thomas

Associate Director, Discovery Chemistry

Mersana Therapeutics

4:00

Pentarins: Miniaturized Drug Conjugates as a Unique Approach for the Treatment of Lung Cancer.

Kerry Whalen

Director of Discovery and Translational Biology

Tarveda Therapeutics

4:30

Development of AVID100, an anti-EGFR ADC with a novel mechanism for tumor-selective cytotoxicity

Victor Goldmacher

Director of Discovery

Formation Biologics